Comparison of One-Tier and Two-Tier Newborn Screening Metrics for Congenital Adrenal Hyperplasia
Open Access
- 1 November 2012
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 130 (5), e1261-e1268
- https://doi.org/10.1542/peds.2012-1219
Abstract
BACKGROUND: Understanding the risk for type 2 diabetes (T2D) early in the life course is important for prevention. Whether genetic information improves prediction models for diabetes from adolescence into adulthood is unknown. METHODS: With the use of data from 1030 participants in the Bogalusa Heart Study aged 12 to 18 followed into middle adulthood, we built Cox models for incident T2D with risk factors assessed in adolescence (demographics, family history, physical examination, and routine biomarkers). Models with and without a 38 single-nucleotide polymorphism diabetes genotype score were compared by C statistics and continuous net reclassification improvement indices. RESULTS: Participant mean (± SD) age at baseline was 14.4 ± 1.6 years, and 32% were black. Ninety (8.7%) participants developed T2D over a mean 26.9 ± 5.0 years of follow-up. Genotype score significantly predicted T2D in all models. Hazard ratios ranged from 1.09 per risk allele (95% confidence interval 1.03–1.15) in the basic demographic model to 1.06 (95% confidence interval 1.00–1.13) in the full model. The addition of genotype score did not improve the discrimination of the full clinical model (C statistic 0.756 without and 0.760 with genotype score). In the full model, genotype score had weak improvement in reclassification (net reclassification improvement index 0.261). CONCLUSIONS: Although a genotype score assessed among white and black adolescents is significantly associated with T2D in adulthood, it does not improve prediction over clinical risk factors. Genetic screening for T2D in its current state is not a useful addition to adolescents’ clinical care.This publication has 22 references indexed in Scilit:
- Structure-Based Analysis of Five Novel Disease-Causing Mutations in 21-Hydroxylase-Deficient PatientsPLOS ONE, 2011
- False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasiaEuropean Journal of Pediatrics, 2007
- Expanded Newborn Screening for Biochemical Disorders: The Effect of a False-Positive ResultPEDIATRICS, 2006
- Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girlsThe Journal of Pediatrics, 2005
- Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia by Second-Tier Steroid Profiling Using Tandem Mass SpectrometryClinical Chemistry, 2004
- Risk factors associated with delayed thyrotropin elevations in congenital hypothyroidismThe Journal of Pediatrics, 2003
- Newborn Screening for Congenital Adrenal Hyperplasia inthe NetherlandsPEDIATRICS, 2001
- Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal HyperplasiaPEDIATRICS, 1998
- Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levelsThe Journal of Pediatrics, 1997
- Consultation with the Specialist: The Vulnerable ChildPediatrics in Review, 1996